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Abstract
Background:  Activation of peroxisome proliferator-activated receptors γ (PPARγ) induces
diverse effects on cancer cells. The thiazolidinediones (TZDs), such as troglitazone and ciglitazone,
are PPARγ agonists exhibiting antitumor activities; however, the underlying mechanism remains
inconclusive. Rosiglitazone (RGZ), a synthetic ligand of PPARγ used in the treatment of Type 2
diabetes, inhibits growth of some tumor cells and is involved in other processes related to cancer
progression. Opposing results have also been reported with different ligands on tumor cells. The
purpose of this study was to determine if RGZ and 15d-PGJ2 induce antitumor effects in vivo and in
vitro on the murine mammary tumor cell line LMM3.
Methods: The effect on LMM3 cell viability and nitric oxide (NO) production of different doses of
RGZ, 15-dPGJ2, BADGE and GW9662 were determined using the MTS colorimetric assay and the
Griess reaction respectively. In vivo effect of orally administration of RGZ on tumor progression
was evaluated either on s.c. primary tumors as well as on experimental metastasis. Cell adhesion,
migration (wound assay) and invasion in Transwells were performed. Metalloproteinase activity
(MMP) was determined by zymography in conditioned media from RGZ treated tumor cells. PPARγ
expression was detected by inmunohistochemistry in formalin fixed tumors and by western blot in
tumor cell lysates.
Results: RGZ orally administered to tumor-bearing mice decreased the number of experimental
lung metastases without affecting primary s.c. tumor growth. Tumor cell adhesion and migration,
as well as metalloproteinase MMP-9 activity, decreased in the presence of 1 µM RGZ (non-
cytotoxic dose). RGZ induced PPARγ protein expression in LMM3 tumors. Although metabolic
activity -measured by MTS assay- diminished with 1–100 µM RGZ, 1 µM-treated cells recovered
their proliferating capacity while 100 µM treated cells died. The PPARγ antagonist Biphenol A
diglicydyl ether (BADGE) did not affect RGZ activity. On the contrary, the specific antagonist
GW9662 completely abrogated RGZ-induced decrease in cell viability. A decrease in NO levels
was detected in the presence of either 1 or 100 µM RGZ. The natural ligand 15d-PGJ2 did not affect
metabolic activity although it induced a significant decrease in NO production.
Conclusion: A significant decrease in the number of experimental LMM3 lung metastasis, but not
on primary tumor growth, after oral RGZ administration was observed. In vitro, 100 µMRGZ also
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reduced cell viability and NO production, while no changes were observed in the presence of 15d-
PGJ2. BADGE did not reverse RGZ effect while the antagonist GW9662 completely abrogated it,
suggesting a PPARγ- dependent mechanism. Inhibition of lung metastatic nodules by RGZ
administered in vivo, might be associated with the observed decrease in MMP-9 expression, in cell
adhesion, migration and invasion. RGZ augmented its expression. PPARγ was detected in cell
lysates by western blot and by immunohistochemistry in tumors from RGZ-treated mice. In
summary we can suggest that RGZ or any other TZDs might be possible future approaches in the
treatment of metastasis of PPARγ-expressing cells.
Background
Peroxisome proliferator activated receptors (PPARs)
belong to a ligand-dependent nuclear receptor family that
regulates multiple metabolic processes associated with β-
oxidation, glucose utilization and cholesterol transport.
Three subtypes of PPARs (α, β/δ and γ) have been identi-
fied exhibiting distinct tissue distribution and associated
with selective ligands [1]. PPARγ is broadly characterized
and it is highly expressed in adipose and adrenal tissues,
colon epithelia, T and B lymphocytes and macrophages.
The heterodimer PPARγ-RXR (retinoic acid receptor)
binds specifically to response elements and works as a
transcription factor [2]. Because of the recruitment of dif-
ferent coactivators PPARγ shows distinctive biological
activities [3]. As seen in monocytes and macrophages, lig-
ands can repress the transcription of proinflammatory
products such as TNF, IL-1 and iNOS (inducible nitric
oxide synthase) [4,5].
The role of PPARs is controversial in tumor biology.
PPARγ ligands have anticancer effects against a wide vari-
ety of neoplastic cells in vitro and in vivo but target genes
involved in this activity remain unclear [6]. Many authors
have documented induction of differentiation and apop-
tosis by ligands of PPARγ, particularly in non-small cell
lung cancer, glioblastoma, prostate, colon, pituitary and
liver cancer cells [6-8]. Invasion of breast cancer cells, that
often express prominent levels of PPARγ, is inhibited by
rosiglitazone (RGZ) in a PPARγ-independent manner [9].
Since we first found that murine mammary LMM3 tumor
cells expressed PPARγ protein, we performed in vivo exper-
iments to analyze the effect of RGZ, the synthetic com-
pound with high affinity for PPARγ, on primary tumor
and lung metastasis development. Furthermore, we stud-
ied the effects of RGZ on tumor cell viability, adhesion,
migration and levels of MMP-9 and NO production.
Activity of the natural ligand 15-deoxy-∆12,14-PGJ2 (15d-
PGJ2) was studied. Experiments with the PPARγ antago-
nist bisphenol A diglycidyl ether (BADGE) [10] and GW
9662 [11] were included to evaluate the roles of PPARγ-
dependent and independent signaling pathways in several
responses. According to our results, RGZ might be consid-
ered as a possible therapeutic, able to inhibit tumor cell
growth in secondary tissues affecting different steps of the
metastatic cascade. The involvement of the inflammatory
milieu associated with tumor development must be also
considered.
Methods
Reagents
15-deoxy-delta12,14-prostaglandin J2 (15d-PGJ2, Cayman
Chemical Company, Ann Arbor, MI, USA) and Rosiglita-
zone -RGZ- (ELEA Lab, Argentina) were dissolved in
100% and 70% ethanol respectively. Bisphenol A diglyci-
dyl ether (BADGE, FLUKA, Chemical GmbH Buchs, Swit-
zerland), was dissolved in 70% ethanol and GW9662
(Sigma-Aldrich, USA) in DMSO. Each of the solvents was
used as a control without significant effect. LPS (Sigma-
Aldrich, Missouri, USA.) was used at 500 µg/ml.
Tumor cell culture
The tumor cell line LMM3, syngeneic to BALB/c, derived
from spontaneous lung metastasis from the primary MM3
mammary tumor, was obtained and established in our
Research Area [12]. LMM3 cells were maintained in MEM
medium (Gibco, BRL) with 3 mM L-glutamine, 80 µM/ml
gentamycin, supplemented with 5% fetal calf serum (FCS)
(Bioser, Argentina) and cultured in a humidified 5% CO2
air atmosphere at 37°C. Serial passages of confluent mon-
olayers were performed by detaching cells with trypsin
(0.25% trypsin and 0.075% EDTA in CA++ and Mg++ free
PBS). Medium was replaced every two days. LMM3 cells
were used for in vitro and in vivo studies.
Cell viability
1 × 104 cells/200 µL MEM + 10% FCS were seeded in 96-
well plates (CELLSTAR, Greiner Bio-One, USA). After 2 h
adhesion, cells were washed and fresh medium with RGZ
or 15d-PGJ2 (0.01–100 uM) without FCS was added.
When used, BADGE (10 µM) was added 15 min and GW-
9662 (1, 10, 20 µM) 1 h before RGZ. After 24 h incuba-
tion, metabolic activity was measured using the MTS assay
(CellTiter96 AQueous Non-radioactive Cell Proliferation
Assay, Promega, USA) an ELISA plate reader (Bio Rad) at
492 nm wavelength. In addition, cells were cultured for
24–48 h with 1–100 uM RGZ and then placed back inBMC Cancer 2008, 8:47 http://www.biomedcentral.com/1471-2407/8/47
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fresh medium for additional 48 h. Number of viable cells
was quantified by Trypan blue exclusion test every 24 h up
to 96 h.
NO production
The level of NO was estimated by measuring nitrite levels
with Griess reagent in extracellular medium from cells
incubated overnight with RGZ and 15d-PGJ2. Briefly, 100
µl cell-free supernatants were added to equal volume of
Griess reagent [13] (1% sulphanyl amine in 30% acetic
acid with 0.1 % N-1-naphtyl ethylendiamine dihydro-
chloride in 60 % acetic acid). Absorbance was measured
at 540 nm with an ELISA reader. Different concentrations
of sodium nitrite were used to construct a standard curve.
In vivo tumor growth
At day 0, female inbred BALB/c mice (aged 6–8 weeks)
were s.c. inoculated into the flank with LMM3 cells (3 ×
105/0.1 ml). After inoculation, mice were randomized
into 2 groups (each with n= 10). One group was adminis-
tered a concentration of 100 µM RGZ in the drinking
water while control group was administered with ethanol
0.01 % v/v. Treatment continued for 30 days (total dura-
tion of the experiment). Animals were scored for tumor
growth three times/week by measuring the smallest and
largest diameters of the s.c. tumors with a Vernier caliper.
At the end of the experiment, some tumors were excised to
determine PPARγ expression. Mice were maintained
under guidelines established in the guide for Care and Use
of Laboratory Animals (NIH publications, 1986).
Experimental metastasis in vivo
2 × 105 LMM3 cells were i.v. injected into the tail vein.
RGZ (100 uM) was administered in the drinking water.
Ethanol was administered to control mice. At day 30 mice
were sacrificed and lungs were examined for metastatic
lesions (number and size) under stereoscopic microscope
(Bausch & Lomb).
Adhesion assay
RGZ (1 µM) was added to LMM3 cells during the process
of adhesion to 6-well plates in the absence of FCS. After 2
h, the number of non-adherent cells was determined by
counting cells in the supernatants ("process of adhesion
assay"). In another set of experiments, RGZ was added for
6h to already attached cells and the number of cells that
could be obtained by aspiration was determined. ("resist-
ance to aspiration assay"). When used, 10 µM BADGE was
added 15 min before RGZ.
Migration Assay
A wound of 400 µm was made on confluent cell monol-
ayers in 6-well plates and 10 µM RGZ with or without
BADGE was added ("wound assay"). Microphotographs
taken immediately after performing the wound (T0) and
24h later (T1) were analyzed using the Image-ProPlus 4.5
software program. Difference between cell-free area at T0
and T1 was quantified.
Invasion assay
50 µl 0.1% gelatine and 100 µl matrigel were loaded in
the lower and upper part respectively of Transwell cham-
bers. Using fibronectin (4 µg/ml) as chemoattractant 2 ×
105 LMM3 were seeded and treated with 1 µM RGZ, 10 µM
BADGE or the combination of both. After 20 h culture at
37°C, membranes were fixed and stained with DAPI. Cell
invasion was determined counting the number of cells
adhered to the membranes using a fluorescence micro-
scope (400× magnification). 10 fields were counted per
group.
Gelatin zymography
Gelatinolytic MMP activity was determined on substrate-
impregnated gels. Briefly, samples were separated on SDS-
9% polyacrylamide gels containing 1 mg/ml copolymer-
ized gelatin (Difco, Detroit, MI) under non-reducing con-
ditions. These gels were washed twice with 2.5% Triton X-
100, incubated for 24 hours at 37°C in 0.25 M Tris-HCl,
1 M NaCl, 25 mM CaCl2 at pH 7.4, and stained with 0.5%
Coomassie G 250 (Bio-Rad, Richmond, CA) in methanol/
acetic acid/water (30:10:60). The clear lysed areas (white
bands) on the stained gels were measured with a GS-700
densitometer (Bio-Rad, Hercules, CA, USA).
Immunohistochemistry
PPARγ expression was analyzed in formalin-fixed, paraf-
fin-embedded sections of LMM3 tumors. Briefly, endog-
enous peroxidase activity was blocked with 0.6 %
hydrogen peroxide. Antigen retrieval was performed using
microwave oven irradiation in citrate buffer (pH: 6).
Slides were incubated for 1 h with normal goat serum
(1:10) (Vector Labs, Burlingame, CA) and overnight with
rabbit specific monoclonal antibody anti-PPARγ (H-100,
Santa Cruz Biotechnology, USA) diluted 1:20. Sections
were incubated with biotinylated goat anti-rabbit IgG
(Sigma-Aldrich) diluted 1:500 for 60 min, followed by
incubation with peroxidase-conjugated streptavidin
diluted 1:3000 in phosphate-buffered saline for 45 min.
Peroxidase reaction was performed using 0.02% 3, 3'-
diaminobenzidine tetrahydrochloride and 0.01% hydro-
gen peroxide and co-staining with hematoxylin (1 min).
As negative control, the primary antibody was omitted.
Detection of PPARγ by western blot
LMM3 cell monolayers were rinsed twice with ice-cold
PBS and scraped into 100 ul RIPA lysis buffer: (50 mM
Tris-HCl, pH 7.5; 150 mM NaCl, 10 mM EDTA, 1%
NP40). Lysis was completed by sonication and centrifuga-
tion. Protein content was determined with Bradford rea-
gent, using bovine serum albumin as standard. SampleBMC Cancer 2008, 8:47 http://www.biomedcentral.com/1471-2407/8/47
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electrophoresis (100 µg protein/25 µl/lane) was per-
formed on 10 % sodium dodecyl sulfate polyacrylamide
gels (SDS-PAGE). Proteins were transferred to nitrocellu-
lose membranes and incubated overnight with mouse
monoclonal antibody anti-PPARγ, diluted 1:100. The sec-
ondary antibody, conjugated with alkaline phosphatase
anti-rabbit IgG (Sigma-Aldrich), was added for 1 h at
37°C. Proteins were visualized using a mixture of NBT/
BCPI (Sigma-Aldrich) and scanned with a computerized
densitometer (GS-700Calibrated Densitometer Bio-Rad
Laboratories, Richmond, CA).
Statistical analysis
Results are expressed as mean ± standard deviation. Sig-
nificance of differences was calculated by Student's t test
or Mann Whitney. All experiments were performed by
triplicate and repeated at least three times, with compara-
ble results.
Results
RGZ and 15d-PGJ2 differentially affect LMM3 cell viability 
and NO production
1 and 100 µM RGZ reduced metabolic activity in 50%,
measured with MTS assay (Fig 1A). To determine if this
inhibition was associated with a decrease in cell viability,
the number of viable cells was quantified every 24 h up to
96 h (Trypan blue exclusion test). After 72 h, control cells
reached a plateau and the number of viable cells quadru-
pled the number of seeded cells. In cells cultured with 1
µM RGZ, no significant increase in cell number was
observed during the first 48 h. At this point cells began to
recover their proliferating capacity, and reached control
numbers at 96 h. On the contrary, cells treated with 100
uM RGZ almost died after 72 h (Fig 1B). 15d-PGJ2 did not
affect metabolic activity.
Since inflammation is an important component of tumor
microenvironment, we examined the effect RGZ in cell
cultures with LPS. Addition of LPS completely abrogated
the inhibitory effect of 1–100 µM RGZ (Fig 1A). Previous
results have shown that NO seems to be a protective/sur-
vival factor for LMM3 cells, since increased cell death was
detected in the presence of NOS inhibitors such as L-
NAME (NG-nitro-L-arginine methyl esther) and AG
(aminoguanidine) (Jasnis MA et al, unpublished results).
NO production decreased 40% in cultures with 10
µM15d-PGJ2 and 1–100 µM RGZ; the presence of LPS
reversed this effect and induced a significant increase in
NO levels (Fig 1C).
Effect of BADGE and GW9662 on cell viability
Since BADGE and GW9662  are PPARγ antagonists, we
studied their effects to assess the relative roles for PPARγ-
dependent and independent biological responses. 10 µM
BADGE and GW9662 (1, 10 and 20 µM) per ser did not
affect cell metabolic activity while higher concentrations
of BADGE were cytotoxic (data not shown). As shown in
Fig 2a, BADGE did not behave as an antagonist. Moreover,
a more significant decrease in metabolic activity with
BADGE + RGZ was detected compared to RGZ alone. The
same effects were observed on NO production (Fig 2a,
numbers between parentheses). On the other hand, GW-
9662, an irreversible PPARγ antagonist, completely
reversed the inhibition of cell metabolic activity induced
by RGZ 1 and 100 µM. (Fig 2b)
Tumor and metastasis growth
Tumor cells were directly inoculated into the tail vein and
differences in lung metastasis were detected between
untreated and RGZ-treated mice: median (range): 21 (5–
Effect of RGZ and 15d-PGJ2 on LMM3 cell viability Figure 1
Effect of RGZ and 15d-PGJ2 on LMM3 cell viability. A. 
MTS assay was used to determine cell metabolic activity after 
24 h-culture in the presence of RGZ (1 and 100 µM) and 
15d-PGJ2 (1 and 10 uM) with or without LPS (500 µg/mL). 
Results are expressed as absorbance (% of control consid-
ered 100%) ***p < 0.001 vs. control. B. The growth-kinetics 
of LMM3 cells in the presence of 10 µM BADGE, 1 and 100 
µMRGZ is shown (**p < 0.01, ***p < 0.001 vs. control). C. 
NO production by LMM3 tumor cells cultured during 24 h 
with RGZ (1 and 100 µM) or 15d-PGJ2 (1 and 10 µM) was 
measured in the supernatants using Griess reagent. Experi-
ments were performed with and without LPS. Results are 
expressed as µM NO2 respect to a control curve of nitrite. A 
and B show the results of one representative experiment of 
three independent assays performed by triplicate with similar 
results. **p < 0.01; ***p < 0.001 vs control.BMC Cancer 2008, 8:47 http://www.biomedcentral.com/1471-2407/8/47
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36) and 7 (0–17) respectively, p < 0.0001 (Fig 3A). These
differences were observed in metastasis with diameters up
to 2 mm. However, oral administration of RGZ did not
affect primary s.c. tumor growth (Fig 3B).
Effect of RGZ on cell adhesion and migration
During early cell attachment (2 h), 1 µM RGZ significantly
inhibited tumor adhesion. The addition of BADGE did
not reverse this effect, and BADGE per se diminished cell
adhesion (Fig 4A). After 8 h adhesion 77% of control cells
were resistant to aspiration. Addition of RGZ diminished
by 50% cell attachment  (50% attached cells) (Fig 4B). It
is noteworthy that BADGE could reverse the inhibitory
effect completely (Fig 4B). A reduction of 59% in tumor
Effect of RGZ on experimental lung metastases and primary  tumor growth Figure 3
Effect of RGZ on experimental lung metastases and 
primary tumor growth. A. Lung metastasis. On day 0, 
mice (n = 10/group) were i.v. inoculated with LMM3 cells 
into the tail vein. Experimental group was orally treated with 
100 µMRGZ while control group only with ethanol in drink-
ing water. On day 30, mice were sacrificed and number and 
size of lung metastatic nodules were recorded under micro-
scope. Each point in the figure represents total number of 
metastases/lung/mice. All nodules were ≤ 2 mm in diameter. 
Median (range) is shown on the horizontal line (p < 0.007). 
One experiment of three with similar results is shown. B. 
Primary tumor. Perpendicular diameters of s.c. growing 
tumors were measured three times/week since day 7 
(latency) up to day 25. Average of tumor size at each point 
was calculated as follows: √(dxD), d = minor diameter, D = 
major diameter. Error bars represent SD (n = 10). No signif-
icant difference was observed at any time during tumor pro-
gression between groups.
A. Effect of BADGE on cell metabolic activity Figure 2
A. Effect of BADGE on cell metabolic activity. BADGE 
(10 µM) was added to cell cultures alone or 15 minutes 
before 100 µM RGZ. After 24 h, metabolic activity was 
determined by MTS assay. BADGE per se had no effect. 
BADGE + RGZ diminished metabolic activity compared to 
RGZ alone (*** p < 0.001). NO levels are shown between 
parentheses (µM). B. Effect of GW-9662 on LMM3 cells. 
GW-9662 (1, 10, and 20 µM) was added to cell cultures 1 h 
before 100 µM RGZ. After 24 h, metabolic activity was 
determined by MTS assay. (*** p < 0.001 vs. control 
untreated cultures).
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cell migration was observed in the presence of RGZ. This
result was not reversed by BADGE -which slightly inhib-
ited cell migration per se. (Fig 4C).
Cell Invasion in Matrigel
RGZ and BADGE at non-toxic doses, alone or in combina-
tion, completely annulled LMM3 cell invasion in Matrigel
(Fig 5).
Production of matrix metalloproteases
MMP activity was analyzed by gelatin and casein zymog-
raphy in conditioned media of control, 1 µM RGZ and 10
µM BADGE treated LMM3 cells. Gelatin zymography
revealed bands corresponding to mouse mammary gland
latent MMP-9 (LMMP-9). A decrease in the levels of
LMMP-9 was detected in conditioned media from RGZ
and BADGE treated cells compared to control untreated
cells. (Fig. 6)
Effects of RGZ on PPARγ expression
Perinuclear staining of PPARγ was detected in almost all
tumor cells from RGZ-treated mice (Fig 7 right panel),
while no expression could be found in tumors from
untreated mice (Fig 7 left panel). In treated and untreated
tumor bearing mice, adipocytes and endothelium showed
intense PPARγ staining. RGZ enhanced the expression of
Effect of RGZ on cell adhesion and migration Figure 4
Effect of RGZ on cell adhesion and migration. A. 
LMM3 cells were cultured with 1 µMRGZ and 10 µM 
BADGE alone or in combination. Non-adherent cells were 
counted after 2 h with a haemocytometer. * p < 0.05 vs. con-
trol. No differences were observed between RGZ and 
RGZ+BADGE. B. Already attached tumor cells were treated 
with RGZ with or without BADGE. The number of detached 
cells after 8 h was considered as a measure of "resistance to 
aspiration" ** p < 0.01 vs. control; * p < 0.05 vs. RGZ; C. 
Cell migration in the presence of 1 µM RGZ, 10 µM BADGE 
or the combination of both was evaluated using the "wound 
assay". The % of covered area after 24 h treatment, com-
pared to control is shown. In all cases representative results 
of three experiments performed by triplicate are shown.
Effect on Cell Invasion in Matrigel Figure 5
Effect on Cell Invasion in Matrigel. Inhibition in cell inva-
sion in matrigel was detected in all cultures, with no differ-
ences between 1 µM RGZ and 10 µM BADGE alone or in 
combination (*p < 0.05).BMC Cancer 2008, 8:47 http://www.biomedcentral.com/1471-2407/8/47
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PPARγ protein in LMM3 cells, compared to control cells
(Western blot, Fig. 7B).
Discussion
The main finding of our experiments is the decrease in the
number of experimental LMM3 lung metastasis after oral
RGZ administration without any effect on primary tumor
growth. Metastasis inhibition could be correlated with in
vitro results of metabolic activity and cell viability reduc-
tion by 100 µMRGZ. 1 µM RGZ only induced the decrease
in metabolic activity without affecting cell viability, sug-
gesting a possible arrest in cell cycle. It is probable that
oral ingestion of a solution 100µM does not reach this
same plasmatic concentration, but most likely achievable
doses obtained in vivo are closer to 1µM., partially explain-
ing the absence of in vivo tumor killing. 10 µM BADGE per
se significantly enhanced the number of viable cells over
control cultures, showing that at non-toxic doses, it was
able to stimulate cell proliferation. Moreover, BADGE not
only did not reverse the inhibitory effect of RGZ, but
instead acted to further decrease cell metabolism (Fig 2A).
Our results agree with those of Lea et al [14] who reported
that BADGE and diclofenac failed to reverse the inhibitory
effect of ciglitazone on growth of human breast cancer
and mouse eritroleukemia cells. Although it has been
widely reported that doses near to 100 uM are needed for
BADGE to behave as a PPAR inhibitor, we could not use
higher doses than 10 uM because, in our system, they were
cytotoxic. BADGE has been shown to serve as a PPARγ
agonist in RAW 264.7 cells, human monocytes and in
some epithelial cells [15,16] and as an inducer of apopto-
sis in some tumor cells [17]. The mechanisms responsible
for the effects of RGZ on LMM3 viability seem to involve
PPARγ-dependent signals since we found that changes in
cell metabolism induced by RGZ were inhibited by
GW9662. Our results agree with those reported using dif-
ferent NSCLC cell lines [11]. Studies with a great variety of
solid and hematological human tumors have demon-
strated the antitumor effects of different TZDs [18-20]. It
has also been reported that RGZ slowed proliferation but
did not induce apoptosis of colon cancer cells [21]. In our
model, inhibition of metabolic activity with 1 uM RGZ
was not associated with cell death but most likely with a
reversible cell cycle arrest, since after 72 h, cultured cells
recovered proliferating capacity. Morosetti et al have
found that after drug removal, cells exposed to RGZ
A. PPARγ expression in LMM3 Figure 7
A. PPARγ expression in LMM3. Representative immu-
nostaining for PPARγ in LMM3 cells from fresh tumor sam-
ples obtained from untreated mice (right panel) and from 
RGZ-orally treated (100 µM) (left panel). Almost all tumor 
cells were positive in tumors from RGZ treated animals 
while no staining was detected in LMM3 cells from tumors 
from untreated animals. Adipocytes and endothelial cells 
were positive in both groups. Photograph magnification, 
×400. B. Western blot and immunostaining of PPARγ. Cell 
lysates were prepared from LMM3 tumor cells treated or 
not with 1 µM RGZ for 24 h. Western blot analysis was per-
formed with specific antibody anti PPARγ.
Effects on MMP activity Figure 6
Effects on MMP activity. MMP activity was determined in 
conditioned media from control LMM3 tumor cells (left), 
1uMRGZ-treated (middle) and 10 µM BADGE-treated cells 
(right). RGZ induced a decrease on the expression of latent 
MMP-9 (LMMP-9) compared to control (*p < 0.05).
CONTROL        RGZ   BADGE 
MMP-9 
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resumed their proliferation, while cells treated with PGJ2
did not overcome the cytotoxic insult [22]. These differ-
ences were associated with an irreversible G2/M arrest
induced by15d-PGJ2 and only transiently by RGZ. LMM3
cell viability was not affected by 15d-PGJ2. The differences
between natural and synthetic ligands can be attributed to
distinctive affinities or potency of both ligands in LMM3
cells. RGZ and 15d-PGJ2 have been shown to exert anti-
proliferative effects on human glioblastoma cell lines but
only PGJ2 modulated the expression of proteins associ-
ated with cell differentiation [22] Differences in the level
of PPARγ may also affect the overall sensitivity of a tumor
cell to activating ligands. The MCF-7 cell line, which
expresses rather low amounts of PPARγ in comparison to
other cell lines, was sensitive only at high concentration of
PGJs [23] Receptor mutations leading to altered binding
affinities or activating effects could also account for differ-
ences on sensitivity [24].
Inhibition of LMM3 lung metastatic nodules by RGZ
might be associated with the observed decrease in MMP-9
expression. Opposite results have been recently reported
demonstrating that, in the HT1080 cell line, pro-MMP-2
was activated by ciglitazone and that the antagonist
GW9662, although attenuated PPARγ activation, had no
effect on MMP-2 [25]. Cell adhesion and adhesion mole-
cules are critical in the processes of invasion and metasta-
sis. The anti-adhesive properties of RGZ were observed
both during the process of LMM3 cell adhesion and dur-
ing de-adhesion of already attached cells. It is interesting
to note that in early adhesion, BADGE and RGZ showed
the same anti-adhesive effect. However, once the cells
were already attached, addition of BADGE reversed RGZ-
induced cell detachment. Combination of RGZ and
BADGE showed that BADGE is not a pure antagonist of
PPARγ since, in the process of early adhesion; it seemed to
act as an agonist ligand. It is noteworthy that loss of
LMM3 cell adhesion was not the result of cell death since
all detached cells were still alive. It has been reported that
PPARγ inhibitors prevented thyroid and hepatocellular
carcinoma cell adhesion by inhibition of FAK phosphor-
ylation and inducing cell death by anoikis [26,27]. Fur-
thermore, in a model of colorectal cancer, it was recently
observed that BADGE was a potent inhibitor of metastases
[28]. It is becoming clear that activation of the same recep-
tor with different ligands may result in different
responses. The anti-metastatic activity of RGZ in vivo,
without affecting primary tumor growth, might be par-
tially attributed to inhibition of cell adhesion, migration
("wound assay") and invasion (Transwell), the latter
being the most sensitive.
The role of PPARγ in tumors has been widely studied.
PPARγ agonists induce apoptosis using fatty acid deriva-
tives, TZDs and tyrosine-based agonists in several cancer
cell types [29]. More recently, perturbation of PPARγ
expression and activity have been suggested as a therapeu-
tic strategy for several epithelial tumor types [30]. Studies
on the expression of PPARγ in LMM3 tumor cells showed
that RGZ augmented its expression. PPARγ was detected
by immunohistochemistry only in tumors from RGZ-
treated mice, while surrounding adipocytes and endothe-
lium were stained in treated and control animals. Accord-
ing to these observations, we cannot discard the fact that
in vivo, the inflammatory tumor microenvironment (mac-
rophages, lymphocytes, endothelial cells) might regulate
PPARγ expression in tumor cells. It has been reported that
serum lysophosphatidic acid attenuates both the degree of
PPARγ activation and the cellular response to 15d-PGJ2 in
neuroblastoma cells [31].
The decrease in NO levels in the presence of RGZ was
dose-independent. LMM3 cells express COX-1, COX-2,
NOS2, NOS3 and arginase II, involved in angiogenesis
and tumor cell migration. We provided evidence that
PGE2 exerted a positive loop on NOS activity in these
tumor cells, augmenting NO levels which closed the loop
with a negative feed-back on COX activity [32]. Pre-
vioulsy, we have reported that LMM3 cells produce high
levels of NO, further increased in the presence of
LPS+IFN, which inversely correlated with sensitivity to
injury by an exogenous source of NO [33]. In the present
experiments, both RGZ and 15d-PGJ2 reduced NO pro-
duction, a survival factor for LMM3 cells (Jasnis MA et al,
unpublished data). In other tumor model, we have
observed that induction of PPARγ expression by BCG,
15d-PGJ2 and RGZ was associated with a decrease in NO
production and loss of cell viability [34].
Since inflammation is an important component of tumor
progression, we analyzed the effect of an inflammatory
stimulus such as LPS on the response of LMM3 cells to
RGZ or 15d-PGJ2. While NO production was augmented
by RGZ, it decreased by 15d-PGJ2. Furthermore, LPS
reversed cell metabolic inhibition induced by RGZ. It has
been reported that LPS suppressed PPARγ expression in
human monocytes [35] and in microglial cultures [36].
Agonists of PPARγ are also able to modulate inflamma-
tory responses in several cells by inhibiting the expression
of proinflammatory cytokines and of inducible NOS and
COX-2 [5,37]. However, other studies have yielded oppo-
site results showing that RGZ increased the inflammatory
response in epithelial cells and in macrophages [38,39].
Conclusion
The current study suggests that RGZ or any other TZDs
should be considered as possible future therapeutics in
the treatment of metastasis of PPARγ-expressing cells.
Since we cannot underestimate the influence of the
inflammatory milieu of the tumor microenvironment, itBMC Cancer 2008, 8:47 http://www.biomedcentral.com/1471-2407/8/47
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will be necessary to understand the mechanism of action
in a more profound way, and to define under which cir-
cumstances these compounds work best in vivo.
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